Omalizumab is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
This report contains market size and forecasts of Omalizumab Biosimilars in global, including the following market information:
Global Omalizumab Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Omalizumab Biosimilars Market Sales, 2017-2022, 2023-2028, (Units)
Global top five Omalizumab Biosimilars companies in 2021 (%)
The global Omalizumab Biosimilars market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
150 mg/mL Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Omalizumab Biosimilars include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech and BiosanaPharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Omalizumab Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Omalizumab Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Units)
Global Omalizumab Biosimilars Market Segment Percentages, by Type, 2021 (%)
150 mg/mL
75 mg/0.5 mL
Global Omalizumab Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Units)
Global Omalizumab Biosimilars Market Segment Percentages, by Application, 2021 (%)
Persistent Asthma
Nasal Polyps
Chronic Idiopathic Urticaria
Global Omalizumab Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Units)
Global Omalizumab Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Omalizumab Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Omalizumab Biosimilars revenues share in global market, 2021 (%)
Key companies Omalizumab Biosimilars sales in global market, 2017-2022 (Estimated), (Units)
Key companies Omalizumab Biosimilars sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Novartis
Glenmark Pharmaceuticals
Selexis
Generium
CuraTeQ
Celltrion Healthcare
Alvotech
BiosanaPharma
Mabpharm
CSPC Pharmaceutical Group
Biomabs
HisunPharm
Grand Pharm